Cem Bostan, Erdem Karacop, Cüneyt Koçaş, Okay Abacı, Ayşem Kaya, Zerrin Yi̇ği̇t

Keywords: Angina, stable, trimetazidine, lipoprotein-associated phospholipase A2


Introduction: We examined the clinical effectiveness of trimetazidine (TMZ), a metabolic anti-ischemic agent, on lipoprotein-associated phospholipase A2 (Lp-PLA2) levels, which is considered a risk factor for cardiovascular events, and on exercise parameters in patients with stable angina pectoris (SAP). Patients and Methods: The study included 30 patients (mean age 62.1 ± 8.3 years; range 47 to 77 years) with SAP and a positive exercise test result. Serum Lp-PLA2 levels were measured at baseline. Exercise testing and Lp-PLA2 measurements were repeated after at least 12 weeks of TMZ treatment. Results: After TMZ treatment, Lp-PLA2 levels decreased significantly (p= 0.006), and workload increased significantly (p= 0.048). Conclusion: Trimetazidine treatment reduces serum Lp-PLA2 levels via shifting cardiac metabolism, resulting in decreased production of free oxygen radicals and inflammation. This finding, together with improvements in exercise test parameters, suggests that TMZ may have a beneficial effect on the prognosis of patients with SAP.